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T HE cobnib~q malabsorption and 
marked variability in cyclosporine 
(CsA) absorption and metabolism makes CsA 
therapy difficult in orthotopic liver transplan-
tation. Alternations in the hepatic function 
would therefore be expected to change the 
pharmacokinetics of CsA. We have studied 
changes in the kinetics of CsA in two types of 
hepatic impairments. 70(k hepatectom~ and 
complete bile duct ligation in dogs.: 
In the present study. we further in\'esti-
gated the inftuence~ of various degrees of liver 
dysfunction upon CsA pharmaCOkinetics b) 
using those two types of liver-impaired canine 
models: the degrees of dysfunction \\ere evalu-
ated by indocyanine green (ICG) kinetics to 
quantitate hepatic functional resen·e. 
METHODS 
The pharmacok,nellcs of CsA were studied in 20 
mongrel dogs after TM~ hepatectomy or complete bile 
duct ligation as models of liver dysfunction. Chanl!cs in 
liver function were monitored by serial measuremenL< of 
serum bilirubin. the muimum remo"al rate II(,G·R_,l. 
and the plasma disappearance rale constanl IfCd·~ 1of 
leG a~ a hepalIC functional re~erve al Iw'O d~ (o ~ or 
<.0 mg 'kg) before and afler surgloI;all~ induced liver 
Impairments.;" 
C,A, " .. as admlnJ5Iered to dogs al ellher ~ mg kg for ;.0 
10 fK~ hour~ fntrayenousl~ (IV I or I ~K~ m~ 'kg or"lf~ 
(POt on t~Do scl'araLt occas,lon; each ~eek after Ihe 
operation for 4 ~ceks Blood sample5 were obtained from 
Juguiar veins JUSI beiore and 025. 0.5. I. 2 . .3.4 6.8, !:. 
I b. and 24 hours after IV admlnlSlralion and 31 I. 2. 3. 4. 
6.8. 12. lb. and :4 hours after PO adming~tralion (sA 
Fro", 1;'1' D'par/",,", of Su'guJ, L'nHUSI/\ of Pili." 
burglr Hl'allh ('tn/l". 
Add,l'SS rl'p"nl "qUI'SIJ 10 S Takal'o. MD. F,r.'1 
Deparlmrnl of Surgtry. HITo.<akl Un/vl''!m School of 
Ml'dlciM. 5 Zaij,,-c/ro. Hirosald 01.1', Ao",orl Prt/I',-
11.1'1'. Japan 036 
C 1988 b.' Grunt' & S"a/lon, Inc 
O(U 1-/345/8Ilj2001-I056S03.00/0 
conccmra 110m were determined by high· perl ,ormance 
uld chromalography (PHLC) as Ihe parent co~n""II~~ 
CsA from whole blood. 
RESULTS 
peyDent~ percent hepatectomy crealed 
nificant liver dysfunction. and these 
impairmenl subjects recovered slo .... i~ I Fig I 
ICG-R", •• t~R reduced by RTKTD~ ~ ?J 
(mean::. SD). and ICG-K \\as redtlced 
61.3::. 9Y;; thefirst ..... eek after theoperat 
The systemic clearance (CLs) of 1\ C~A \.\ 
reduced by 43,99; !: 8.2SC. but later the 
reco\ered rapldl~K There ..... a!> a signifi 
prolongation of the lerminal half-life of 
CsA only in the first week. Ho .... ever. 
steady-state distribution volume of 1\' C 
.....as not significantly different afler 
hepatectomy .due to too much variability. 
percent bioavailability of PO CsA " 
reduced by 26.4% !: 14.8% (P < .05) the fi 
..... eek. and later it had recovered to .... ithin t 
normal range. After hepatectomy, ~ signIfi-
cant poSit i\'e correlation was obsened be-
tween ICG-Rna. and the CLs of 1\ Cs-\ (r_ 
KS~K P .' .0 II. Also a SIgnificant negatl\C 
correlation was observed bet ..... een serial ~erum 
bilirubin level5 and the percent bioavaliabiilty 
(R = -.67. P < .0 I), However. no ~ignificant 
correlation was observed bety.een seriai sen.i1Ti 
bilirubin levels and the CLs of IV C~-y 
Bile duct ligalJon also Induced another type 
of liver Impairment (Fig 2 L ICG- R"",. was 
reduced by ~9 I E~ = 12,SS( the seconc yyee~ 
and 4RKRE~ ::. 9.9SC the third week after the 
operation. Durrng the same periods. the CLs 
.... ere reduced by 24.3% !: 13.0C;} and PSK1~ : 
TK9~K respectively: the area under the curve 
(ALT) of PO CsA was reduced by S9K9~ :: 
10.7t;; and 60.8% = 15.1 ~K respectivel~K The 
percent bioavailability was reduced b~ 
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• IS.tir; the second week and by 
'3.,.('., ..... ~K:KKK t I Uc; the third week after bile duct 
_I11III" HO'o\e\er no significant negative cor-
,,'';:'-__ was observed between serial serum 
~~"11K"" k\els and the rercent bioavailability 
bile duel ligation. 
DISCUSSION 
is extensively metabolized and elimi-
in the bile. but analysis of bile by HPLC 
XA.-.PICS that b~ than 1 c;r of the administered 
i<Di!1Ki~I;fffff~ of CsA i~ secreted unchanged in the 
urine. Therapeutic drug monitoring of the 
CsA-treated patient i!> necessary because it is 
difficult to ::!ssess interindi\'idual variations in 
CsA absorption. distribution. metabolism. 
and elimmatlon. Actually. in liver transplant 
patients. it is much more difficult to establish 
near-basal values and the steady-state condi-
tion because the liver is the major site of CsA 
metabolism. Kahan 6 reported that patients 
with impaired hepatic function cleared the 
drug one third more slowl~K thereby leading to 
an increased ALT from a demographic analy-
f"y~f~K--------~~--~--~--~~~~~~-------mreo~ Flrll 'wee. S.cond ", .. It Thud' "'HI Fount: _I 
Fig 2. Changa. in pareent 
decra •• ing rata. of hapatic 
functional ... arva and kinatic. 
paramata .. of C.A atta, com-
plata bila duct ligation. ", •• lts .It., opernlOn 
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sis using radioimmunoassay (R I A). However. 
because the primary metabolites of CsA do 
not have signIficant immunosuppressant ac· 
tivity in animal~ and have not been tested in 
humans ~ and because the deterioration of 
hepatic function secondary to rejection or 
hepatic thrombosis frequently produced a dis· 
proportionate me in the RIA blood concen· 
tration. the use of RIA in the setting of altered 
hepatic function grossly underestimates the 
required CsA dosage to achieve the usual CsA 
parent compound level' I n our experiments 
using the HPLC method of whole blood for 
the measurement of the parent compound. on 
the first week the hepatic dysfunction created 
by hepatectomy produced a 44Cff reduction of 
the CLs of IV CsA and a 15) o/r prolongation 
of the terminal half-life (7.65 v 5.06 hours as 
control). This suggested that the interdose 
interval should be prolonged one half longer 
than that for the normal hepatic functional 
group. 
TAKA 'vA Ei AJ. 
The asses:.ment of the hepatic dysfunction 
influence on (sA kinetic~ was reported bv 
uSing elevated ~erum bil iru bi n leve\s.9.lo In Ou'r 
data. significant negative correlation wa~ 
observed between serial serum bilirubin levels 
and percent bioavailability following hepatec. 
tomy. However no significant correlation \\as 
observed between serial bilirubin levels and 
the CLs of IV CsA. Furthermore. in complete 
bile duct ligation. no significant negative cor. 
rela tion was observed a mong the serial serum 
bilirubin levels. the percent bioJ\·ailabilit\. 
and the CLs. . 
These data demonstrate that liver impair. 
ment significantly influence~ the pharmacoki. 
netics of CsA. by not onl) creating changes in 
intestinal absorption but also in hepatic 
metabolism. Safe and effective therapy \.\ill 
require an improved understanding of how 
CsA pharmacokinetics varies with the degree 
and cause of hepatic dysfunction. 
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